NPPB and aortic stenosis: Therefore, although both trials highlight the prognostic value of NT-proBNP and hs-cTnT in asymptomatic severe AS, current evidence suggests that these biomarkers alone are insufficient to guide clinical decision-making regarding the timing of TAVR.